Agnete Witness Præst Jensen (Agnete W P Jensen)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

High Performance Liquid Chromatography

Gene Expression

Top Venues

Seminars in immunopathology

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer immunology research

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Siri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, Ulla Kring Hansen, Maria Ormhøj, Alexander Tyron, Agnete Witness Præst Jensen, Mohammad Kadivar, Amalie Kai Bentzen, Kamilla K Munk, Gitte N Aasbjerg, Jeppe S H Ternander, Christina Heeke, Tripti Tamhane, Christian Schmees, Samuel A Funt, Julie Westerlin Kjeldsen, Anders Handrup Kverneland, Özcan Met, Arianna Draghi, Søren Nyboe Jakobsen, Marco Donia, Inge Marie Svane, Sine Reker Hadrup
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy. Journal for immunotherapy of cancer 11 (8) (2023)
Arianna Draghi, Mario Presti, Agnete Witness Præst Jensen, Christopher Aled Chamberlain, Benedetta Albieri, Anne-Christine K Rasmussen, Mads Hald Andersen, Michael Douglas Crowther, Inge Marie Svane, Marco Donia
Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Giulia Franciosa, Anders Handrup Kverneland, Agnete Witness Præst Jensen, Marco Donia, Jesper Velgaard Olsen
Proteomics to study cancer immunity and improve treatment. Seminars in immunopathology (2023)
Morten Nielsen, Mario Presti, Zsófia M Sztupinszki, Agnete Witness Præst Jensen, Arianna Draghi, Christopher Aled Chamberlain, Aimilia Schina, Christina Westmose Yde, John B Wojcik, Zoltan Szallasi, Michael Douglas Crowther, Inge Marie Svane, Marco Donia
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy. Cancer immunology research 10 (10) (2022)